Comparing the current results to its competitors, Savara Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.81 %, recorded in the same quarter.
Savara Inc , slower than the average decrease reported by the company's competitors of -50.77 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -50.77 %
Savara Inc 's Comment on Competition and Industry Peers
The company has agreements with PARI concerning the supply of the PARI eFlow® Nebulizer System and accessories. It operates in the pharmaceutical, biotechnology, and related markets with a focus on rare respiratory diseases. The industry is highly competitive and subject to continuous technological change. Competitors include large pharmaceutical and biotechnology companies, specialty companies, and PARI. Regulatory exclusivities, such as orphan drug exclusivity and patent protections, may prevent competitors from marketing similar products for specified periods.
October 24, 2025
Investors in Savara Inc. (NASDAQ: SVRA) are being alerted to the critical deadline for participation in a class action lawsuit against the company. The Rosen Law Firm and Bragar Eagel and Squire, P.C. have both issued notices regarding the need for affected investors to secure legal representation before the imminent deadline of November 7, 2025. This article provides an overview of the situation, outlines the implications for investors, and discusses the ongoing legal actions. Savara Inc., a biopharmaceutical company focused on the development of novel therapies, is currently facing a securities class action lawsuit filed on behalf of investors who purchased its securities between March 7, 2024, and May 23...
October 8, 2025
Savara Inc., a biopharmaceutical company specializing in respiratory medicines, is currently navigating a complex landscape of regulatory setbacks and legal entanglements that could profoundly affect its market positioning and financial health. Both its investor relations and drug development pipeline are under scrutiny, primarily driven by challenges related to one of its cornerstone projects, the MOLBREEVI biologics license application (BLA). This article dives into the multifaceted situation confronting the company, outlines the key facts, and evaluates their potential impact on its future. The Core of the Issue: MOLBREEVI BLASavara Inc. was riding on the promising potential of MOLBREEVI, a therapeutic ai...
September 20, 2025
Rosen Law Firm Leads the Charge in Savara Inc. Class Action as Investors Urged to Secure Representation Before Imminent Deadline NEW YORK, September 20, 2025 - In a significant development for investors in Savara Inc. (NASDAQ: SVRA), Rosen Law Firm, a highly regarded global law firm specializing in investor rights, has announced the initiation of a class action lawsuit. This legal action represents individuals who purchased Savara securities between March 7, 2024, and May 23, 2025. With the stock trading at $3.53, investors are faced with an urgent call to secure legal counsel as the deadline for lead plaintiff applications looms on November 7, 2025.The class action lawsuit arises in a context where Savara...
September 19, 2025
The biopharmaceutical landscape is experiencing turbulence, as several notable companies face legal challenges that have captured the attention of investors. In recent developments, Bragar Eagel and Squire, P.C., a respected shareholder rights law firm, has issued reminders to stockholders about class action lawsuits filed against Tronox Holdings plc (NYSE: TROX), Savara Inc. (NASDAQ: SVRA), Quantum Corporation (NASDAQ: QMCO), and Fly-E Group, Inc. (NASDAQ: FLYE). Shareholders are encouraged to act swiftly, as they have until specific deadlines to petition the courts to serve as lead plaintiffs in these cases.One standout in this scenario is Savara Inc., which has reported a concerning stagnation in revenue....
November 23, 2024
Savara s Phase 3 IMPALA-2 Trial on Inhaled Molgramostim: A Promising Step for Autoimmune Pulmonary Alveolar Proteinosis Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focusing on innovative solutions for rare respiratory disorders, has announced an encore presentation at the prestigious British Thoracic Society (BTS) Winter Meeting, scheduled from November 27-29, 2024, in London, England. The core subject of this presentation is the Phase 3 IMPALA-2 trial, which explores the efficacy of Molgramostim Inhalation Solution (Molgramostim) in treating patients with autoimmune pulmonary alveolar proteinosis (aPAP).Molgramostim, an inhalable treatment, has shown promising results that could s...
October 1, 2024
As the medical field continues to evolve, the focus on patient-centered approaches is becoming increasingly crucial, particularly in rare diseases. Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company committed to addressing unmet needs in rare respiratory conditions, has made exci...
September 27, 2024
In the realm of rare respiratory diseases, advancements in treatment options can substantially alter the landscape of patient care. Savara Inc. a clinical-stage biopharmaceutical company recognized for its commitment to addressing unmet medical needs in respiratory diseases, has recently announced the launch of an Expanded Access Program (EAP) for its investigational drug, molgramostim inhalation solution. This initiative is particularly focused on providing access to molgramostim for patients suffering from Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare and debilitating lung condition. Understanding Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Autoimmune pulmonary alveolar proteinosis is chara...
September 6, 2024
: This article discusses Savara Inc. s recent announcement regarding an employment inducement grant, highlighting the company s strategic moves in the pharmaceutical landscape. Given its current share price of $4.42, this development could reflect both opportunities and challenges as the company seeks to attract and retain talent in a competitive market. Savara Inc.: Strategic Employment Inducement in a Competitive Marketplace Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focused on developing innovative therapies for rare respiratory diseases, has made waves in the pharmaceutical sector with its recent announcement of an employment inducement grant. As of the writing of this article, Savara’s ...
May 16, 2024
In recent news, clinical stage biopharmaceutical company Savara Inc. (Nasdaq: SVRA) has made significant strides towards advancing its mission of addressing rare respiratory diseases. Two key announcements have recently been made, shedding light on the company s ongoing expansion efforts and involvement in networking opportunities. This article delves into the facts surrounding Savara s new employment inducement grant and its participation in the upcoming Citizens JMP Life Sciences Conference.Grant of Inducement AwardsOn May 14, 2024, the Compensation Committee of Savara s Board of Directors awarded inducement grants to a new employee who recently joined the company. The highlights of this grant include opti...
May 9, 2024
The clinical-stage biopharmaceutical industry received the latest updates on the financial insights and business progress of Savara Inc. (Nasdaq: SVRA), a company recognized for its innovative research focused on developing solutions for rare respiratory diseases. The promising biopharmaceutical company, headquartered in Langhorne, Pennsylvania, recently put forth the details of its financial results for the first quarter of 2024, coupled with a business update illustrating the company s current operations and future plans. The financial report, ending on March 31, 2024, painted a positive picture of Savara s fiscal health and ongoing progress in its clinical trials. These triumphs on the economic front hold...
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Sources:
Savara Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Savara Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
